Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

From K Street to Wall Street

This article was originally published in RPM Report

Executive Summary

The Pharmaceutical Research & Manufacturers of America spends a lot of time lobbying for drug interests and trying to improve the industry's public relations image. But how much of what PhRMA does impacts individual drug company stock prices? The answer, according to top prescription drug analysts, is not much.

You may also be interested in...



Big Pharma's Best Friend

The Institute of Medicine report on drug safety has put the focus directly on the Food and Drug Administration. Out of the spotlight, Big Pharma's image is recuperating. It won't last long though.

Measuring Success In Part D: One Beneficiary at a Time

As the Medicare drug benefit gets underway in January 2006, Wall Street analysts will be looking at one metric to gauge the program's success: the number of patients that voluntarily enroll in a stand-alone drug plan. And the early numbers are not promising. Just 1 million patients enrolled in a PDP ahead of the benefit's official kick-off. Pharma needs Part D to succeed: a failure could lead to price controls.

QUOTED. 28 September 2020. Kyle Sampson.

If President Trump appoints, and the Senate approves, a new conservative justice for the Supreme Court to replace Ruth Bader Ginsberg, Affordable Care Act coverage could disappear. See what Kyle Sampson, a partner with the Washington, DC law firm King & Spalding said about it here.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel